As of 11:16 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | 0.88 | 0.82 | 3.33 | 3.64 |
| Low Estimate | 0.84 | 0.8 | 3.31 | 3.46 |
| High Estimate | 0.89 | 0.85 | 3.35 | 3.78 |
| Year Ago EPS | 0.81 | 0.75 | 3.01 | 3.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 10 |
| Avg. Estimate | 334.57M | 326.9M | 1.32B | 1.4B |
| Low Estimate | 332.8M | 324M | 1.32B | 1.39B |
| High Estimate | 335.93M | 330M | 1.33B | 1.41B |
| Year Ago Sales | 310.45M | 306.27M | 1.26B | 1.32B |
| Sales Growth (year/est) | 7.80% | 6.70% | 5.20% | 5.50% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.75 | 0.65 | 0.76 | 0.71 |
| EPS Actual | 0.81 | 0.75 | 0.81 | 0.77 |
| Difference | 0.06 | 0.1 | 0.05 | 0.06 |
| Surprise % | 8.00% | 15.40% | 6.60% | 8.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.88 | 0.82 | 3.33 | 3.64 |
| 7 Days Ago | 0.88 | 0.82 | 3.33 | 3.64 |
| 30 Days Ago | 0.88 | 0.82 | 3.33 | 3.64 |
| 60 Days Ago | 0.88 | 0.83 | 3.32 | 3.64 |
| 90 Days Ago | 0.88 | 0.83 | 3.31 | 3.64 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MMSI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.60% | -- | -- | 7.70% |
| Next Qtr. | 9.30% | -- | -- | 10.30% |
| Current Year | 10.60% | -- | -- | 4.40% |
| Next Year | 9.30% | -- | -- | 12.00% |
| Next 5 Years (per annum) | 10.77% | -- | -- | 11.27% |
| Past 5 Years (per annum) | 20.96% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 5/1/2024 |
| Maintains | Barrington Research: Outperform to Outperform | 5/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 5/1/2024 |
| Maintains | Needham: Buy to Buy | 5/1/2024 |
| Maintains | Barrington Research: Outperform to Outperform | 4/16/2024 |
| Initiated | CL King: Buy | 4/11/2024 |
Related Tickers
UTMD Utah Medical Products, Inc.
66.75
-0.04%
ICUI ICU Medical, Inc.
117.41
+3.34%
LMAT LeMaitre Vascular, Inc.
79.77
-0.40%
ATRI Atrion Corporation
451.99
+0.20%
HAE Haemonetics Corporation
85.38
+0.85%
ATRC AtriCure, Inc.
20.42
-1.64%
NYXH Nyxoah S.A.
7.95
+1.77%
COO The Cooper Companies, Inc.
92.12
-1.44%
ALC Alcon Inc.
88.21
-2.72%
DXR Daxor Corporation
8.83
+3.64%